TNFSF13 and systemic lupus erythematosus: As such, this molecule along with BAFF were rational targets for new therapies in B cell-driven autoimmune diseases, such as the BAFF/APRIL dual inhibitor, atacicept and the BAFF inhibitor, belimumab which is approved as an add-on therapy for active SLE (Samy et al. 2017), however, more preclinical and clinical studies on APRIL are still needed in RA.